^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    VB10.NEO

    i
    Other names: VB10.NEO
    Associations

    News

    Trials
    Company:
    Nykode Therap, Roche
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    11d
    Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, Nykode Therapeutics ASA | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    CRP (C-reactive protein)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • VB10.NEO
    5ms
    Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, Nykode Therapeutics ASA | Phase classification: P1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    CRP (C-reactive protein)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • VB10.NEO
    over1year
    Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors (clinicaltrials.gov)
    P1b, N=60, Recruiting, Nykode Therapeutics ASA | N=40 --> 60
    Enrollment change • Combination therapy • Metastases
    |
    CRP (C-reactive protein)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • VB10.NEO
    over2years
    Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors (clinicaltrials.gov)
    P1b, N=40, Recruiting, Vaccibody AS | Initiation date: Aug 2021 --> Dec 2021
    Trial initiation date • Combination therapy
    |
    CRP (C-reactive protein)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • VB10.NEO
    over2years
    Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors (clinicaltrials.gov)
    P1b, N=40, Recruiting, Vaccibody AS
    Clinical • New P1 trial • Combination therapy
    |
    CRP (C-reactive protein)
    |
    Tecentriq (atezolizumab) • VB10.NEO